GFM
CRNX

GF Fund Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

GF Fund Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$82.9K Buy
2,216
+85
+4% +$3.16K ﹤0.01% 350
2026
Q1 		$77.4K Buy
2,131
+267
+14% +$11.9K ﹤0.01% 361
2025
Q4 		$86.8K Sell
1,864
-162
-8% -$7.21K ﹤0.01% 359
2025
Q3 		$84.4K Sell
2,026
-349
-15% -$11.2K ﹤0.01% 346
2025
Q2 		$68.3K Hold
2,375
– – ﹤0.01% 392
2025
Q1 		$79.7K Buy
2,375
+428
+22% +$16K ﹤0.01% 380
2024
Q4 		$99.5K Buy
+1,947
New +$109K ﹤0.01% 333

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GF Fund Management's CRNX Position: Q2 2026 in Review

GF Fund Management increased its Crinetics Pharmaceuticals (CRNX) stake by 4% in Q2 2026, buying an estimated $3.16K and bringing the position to 2,216 shares worth $82.9K. The position accounts for ﹤0.01% of the portfolio, ranked #350.

GF Fund Management first reported a position in CRNX in Q4 2024 and has held it in 7 quarters since. The position peaked at $99.5K in Q4 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • GF Fund Management held 2,216 shares of Crinetics Pharmaceuticals worth $82.9K as of Q2 2026.
  • GF Fund Management bought 85 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $3.16K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #350 holding.
  • GF Fund Management first reported a position in Crinetics Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • GF Fund Management's Crinetics Pharmaceuticals position peaked at $99.5K in Q4 2024.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.